You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 10,307,417


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,307,417 protect, and when does it expire?

Patent 10,307,417 protects RELISTOR and is included in one NDA.

This patent has fifty-four patent family members in thirty-one countries.

Summary for Patent: 10,307,417
Title:Oral formulations and lipophilic salts of methylnaltrexone
Abstract: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
Inventor(s): Shah; Syed M. (Delray Beach, FL), Diorio; Christopher Richard (Campbell Hall, NY), Ehrnsperger; Eric C. (New City, NY), Meng; Xu (San Diego, CA), Al Shareffi; Kadum A. (Greensboro, NC), Cohen; Jonathan Marc (Monroe, NY)
Assignee: Wyeth, LLC (Madison, NJ)
Application Number:16/219,681
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,307,417
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Device; Dosage form;
Patent landscape, scope, and claims:

Analyzing the Scope and Claims of United States Patent 10,307,417: A Comprehensive Guide

Introduction

Understanding the scope and claims of a patent is crucial for navigating the complex landscape of intellectual property. This article will delve into the details of United States Patent 10,307,417, exploring its claims, scope, and the broader patent landscape it inhabits.

Understanding Patent Claims

Patent claims are the most critical part of a patent application, as they define the scope of the invention and what is protected by the patent. Claims must be clear, concise, and supported by the patent's description and drawings[3].

Patent 10,307,417 Overview

To analyze the scope and claims of United States Patent 10,307,417, one must first identify the patent's title, inventors, and the technology it covers. Here is a general outline:

Title and Inventors

  • Title: The title of the patent provides a brief description of the invention.
  • Inventors: The inventors listed are those who conceived the idea and reduced it to practice[5].

Technology Covered

  • Field of Invention: This section describes the area of technology to which the invention pertains.
  • Background of the Invention: This part explains the context and any prior art related to the invention.

Detailed Claim Analysis

Independent Claims

Independent claims stand alone and define the invention without reference to other claims. These claims are typically broader and more significant.

Dependent Claims

Dependent claims refer back to and further limit an independent claim. They narrow down the scope of the invention and often provide additional details.

Claim Scope Concepts

To understand the full scope of the patent, it is helpful to categorize claims by overarching scope concepts. This involves linking similar claims across different patents to identify coverage gaps and opportunities[3].

Patent Landscape Analysis

Patent Family

A patent family includes all related applications filed at different intellectual property offices. Tools like the USPTO's Global Dossier can help identify the patent family and related applications[4].

Claim Coverage Matrix

A Claim Coverage Matrix is a tool used to show which patents and claims are actively protecting the intellectual property. It helps in identifying gaps or opportunities in the patent coverage[3].

Competitor Analysis

Analyzing competitors' patents in the same field can provide insights into the competitive landscape. This involves tracking patents by claims and scope concepts to understand where competitors are focusing their intellectual property efforts.

Determining Inventorship

Correctly determining inventorship is crucial for the validity of the patent. The true and only inventors must be listed, as errors can lead to the patent being declared invalid or unenforceable[5].

Conception and Reduction to Practice

Inventorship involves two key steps: the conception of the idea and the reduction of the idea to practice. Only those who contributed to these steps should be listed as inventors.

Correcting Errors in Inventorship

While errors in inventorship can be corrected, deceptive intent in naming inventors can render the patent unenforceable. It is essential to ensure that the correct inventors are identified from the outset.

Patent Term and Adjustments

The term of a patent can be affected by various factors, including delays during the prosecution process. Patent Term Adjustments (PTA) and Patent Term Extensions (PTE) can extend the life of a patent, but these must be carefully considered in the context of obviousness-type double patenting (ODP) analyses[1].

Patent Term Adjustment (PTA)

PTA is granted for delays caused by the USPTO, such as delays in issuing the patent beyond three years from the filing date. This adjustment ensures that the patent term is not unfairly shortened due to administrative delays.

Patent Term Extension (PTE)

PTE can be granted under specific circumstances, such as regulatory delays. However, terminal disclaimers and PTA must be considered to avoid ODP issues.

Obviousness-Type Double Patenting (ODP)

ODP prevents an inventor from securing a second, later-expiring patent for an invention covered by a patent that was filed at the same time but has a different patent term due to PTA or other adjustments. This is a critical consideration when managing a family of related patents[1].

Key Takeaways

  • Clear Claims: Ensure that patent claims are clear, concise, and supported by the patent's description and drawings.
  • Inventorship: Correctly identify and list the true and only inventors to avoid patent invalidity.
  • Patent Landscape: Use tools like the Claim Coverage Matrix and Global Dossier to analyze the patent landscape and identify gaps or opportunities.
  • Patent Term Adjustments: Understand how PTA and PTE can affect the patent term and ensure compliance with ODP regulations.

FAQs

Q: What is the importance of correctly identifying inventors in a patent application?

Correctly identifying inventors is crucial because errors can lead to the patent being declared invalid or unenforceable. Only the true and only inventors should be listed to avoid such consequences[5].

Q: How does the USPTO's Global Dossier help in patent landscape analysis?

The Global Dossier provides access to the file histories of related applications from participating IP Offices, allowing users to see the patent family, dossier, classification, and citation data. This helps in identifying related applications and understanding the broader patent landscape[4].

Q: What is the difference between Patent Term Adjustment (PTA) and Patent Term Extension (PTE)?

PTA is granted for delays caused by the USPTO during the prosecution process, while PTE is granted for regulatory delays or other specific circumstances. Both can extend the patent term but must be considered in the context of ODP analyses[1].

Q: How can a Claim Coverage Matrix help in managing a patent portfolio?

A Claim Coverage Matrix shows which patents and claims are actively protecting the intellectual property and where gaps or opportunities exist. It helps in categorizing patents by claims and scope concepts, making it easier to review patent coverage and identify future design opportunities[3].

Q: What are the consequences of deceptive intent in naming inventors on a patent application?

Deceptive intent in naming inventors can render the patent unenforceable. Even if the correct inventorship can be established later, a patent obtained through fraud remains invalid and unenforceable[5].

Sources

  1. In re Cellect - United States Court of Appeals for the Federal Circuit, August 28, 2023.
  2. U.S. Patent and Trademark Office (USPTO) - USA.gov.
  3. Patent Analytics - Schwegman Lundberg & Woessner, P.A.
  4. Search for patents - USPTO.
  5. Determining Inventorship for US Patent Applications - Oregon State University.

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 10,307,417

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Salix RELISTOR methylnaltrexone bromide TABLET;ORAL 208271-001 Jul 19, 2016 RX Yes Yes 10,307,417 ⤷  Subscribe Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.